-
公开(公告)号:US06919183B2
公开(公告)日:2005-07-19
申请号:US10050279
申请日:2002-01-16
申请人: James P. Fandl , Neil Stahl , Gang Chen , George D. Yancopoulos
发明人: James P. Fandl , Neil Stahl , Gang Chen , George D. Yancopoulos
IPC分类号: A01K67/027 , C07K14/315 , C07K14/52 , C07K16/28 , C12N5/10 , C12N15/09 , C40B30/04 , G01N33/569 , G01N33/68 , G01N33/53 , C12N21/02 , C12N21/08
CPC分类号: C40B30/04 , A01K2217/05 , A01K2267/01 , C07K14/315 , C07K14/52 , C07K16/2863 , C07K2317/77 , C07K2319/00 , C12N15/1051 , G01N33/56966 , G01N33/6845 , G01N2500/10
摘要: A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.
摘要翻译: 用于鉴定和分离产生分泌蛋白的细胞的方法。 该方法基于通过瞬时捕获单个细胞表面上的分泌蛋白质的分泌蛋白质的特定特征或表达水平,允许从异质群体中选择稀有细胞克隆。 还提供了这种方法用于产生产生具有特定特征的所需水平的分泌蛋白质或分泌蛋白质的细胞以及具有这种细胞的生物体的用途。 特别地,该方法允许高表达重组抗体产生细胞系的快速分离,或者可以直接应用于快速分离特异性杂交瘤,或分离产生抗体的转基因动物。 该方法适用于分泌蛋白质的任何细胞。
-
公开(公告)号:US20090137416A1
公开(公告)日:2009-05-28
申请号:US12240541
申请日:2008-09-29
申请人: James P. Fandl , Gang Chen , Neil Stahl , George D. Yancopoulos
发明人: James P. Fandl , Gang Chen , Neil Stahl , George D. Yancopoulos
CPC分类号: G01N33/6854 , C12N15/65 , G01N33/566 , G01N33/56966 , G01N2333/7051
摘要: A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has a T cell receptor variable domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.
摘要翻译: 一种检测和分离产生具有T细胞受体可变区的目标分泌蛋白质(POI)的细胞的方法,包括:a)通过以下步骤构建细胞系:瞬时或稳定表达结合POI的细胞表面捕获分子,通过 用编码这种细胞表面捕获分子的核酸转染细胞系; b)同时或随后用编码POI的第二核酸同时转染所述细胞,其中所述POI被分泌; c)通过使细胞与结合POI的检测分子接触来检测表面显示的POI; 和d)基于检测分子分离细胞。
-
公开(公告)号:US07306799B2
公开(公告)日:2007-12-11
申请号:US11089803
申请日:2005-03-25
申请人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
发明人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
CPC分类号: C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译: 公开了具有改善的药物动力学和改善的组织穿透的修饰的嵌合多肽,其可用于治疗眼睛疾病,包括年龄相关性黄斑变性和糖尿病性视网膜病变。
-
公开(公告)号:US20080220004A1
公开(公告)日:2008-09-11
申请号:US11998709
申请日:2007-11-30
申请人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
发明人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
IPC分类号: A61K39/395 , A61K38/02
CPC分类号: C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译: 公开了具有改善的药物动力学和改善的组织穿透的修饰的嵌合多肽,其可用于治疗眼睛疾病,包括年龄相关性黄斑变性和糖尿病性视网膜病变。
-
公开(公告)号:US07521049B2
公开(公告)日:2009-04-21
申请号:US11998709
申请日:2007-11-30
申请人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
发明人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
CPC分类号: C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译: 公开了具有改善的药物动力学和改善的组织穿透的修饰的嵌合多肽,其可用于治疗眼睛疾病,包括年龄相关性黄斑变性和糖尿病性视网膜病变。
-
公开(公告)号:US07303747B2
公开(公告)日:2007-12-04
申请号:US11218234
申请日:2005-09-01
申请人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
发明人: Stanley J. Wiegand , Nicholas J. Papadopoulos , George D. Yancopoulos , James P. Fandl , Thomas J. Daly
CPC分类号: C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
-
7.
公开(公告)号:US08568721B2
公开(公告)日:2013-10-29
申请号:US13462938
申请日:2012-05-03
申请人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号: A61K39/395
CPC分类号: A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译: 本发明提供使用特异性结合人白细胞介素-6受体(hIL-6R)的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂,例如非甾体抗炎药(NSAID),糖皮质激素,疾病缓解性抗风湿药(DMARD)中的一种或多种,或 TNF-α拮抗剂,T细胞阻断剂,抗CD20抗体,IL-1,JAK或IL-17拮抗剂或其任何组合。
-
8.
公开(公告)号:US08192741B2
公开(公告)日:2012-06-05
申请号:US13286261
申请日:2011-11-01
申请人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号: A61K39/395
CPC分类号: A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译: 本发明提供使用特异性结合人白细胞介素-6受体(hIL-6R)的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂,例如非甾体抗炎药(NSAID),糖皮质激素,疾病缓解性抗风湿药(DMARD)中的一种或多种,或 TNF-α拮抗剂,T细胞阻断剂,抗CD20抗体,IL-1,JAK或IL-17拮抗剂或其任何组合。
-
公开(公告)号:US20120003697A1
公开(公告)日:2012-01-05
申请号:US13230081
申请日:2011-09-12
申请人: Sean STEVENS , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Sean STEVENS , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
CPC分类号: C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
摘要翻译: 提供了以约500pM以下的KD结合人IL-6受体(hIL-6R)的人抗体或抗原结合片段,并且以200pM以下的IC 50阻断IL-6活性。 在优选的实施方案中,抗体抗体或抗原结合片段以相对于其结合猴IL-6R至少高2倍的亲和力结合hIL-6R。
-
公开(公告)号:US20130157313A1
公开(公告)日:2013-06-20
申请号:US13450011
申请日:2012-04-18
申请人: Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号: C07K16/28
CPC分类号: C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
摘要翻译: 提供了以约500pM以下的KD结合人IL-6受体(hIL-6R)的人抗体或抗原结合片段,并且以200pM以下的IC 50阻断IL-6活性。 在优选的实施方案中,抗体抗体或抗原结合片段以相对于其结合猴IL-6R至少高2倍的亲和力结合hIL-6R。
-
-
-
-
-
-
-
-
-